Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma

Raymond Lenhard, L. A. Kalish, M. M. Oken, David S Ettinger, J. Glick

Research output: Contribution to journalArticle

Abstract

Background. This study was designed to examine the efficacy and toxicity of high-dose cyclophosphamide (CY), and to evaluate the potential added effect of vincristine (VCR) given at a theoretic time of malignant cell stimulation in a group of patients with multiple myeloma, refractory to or relapsing after, treatment with standard doses of chemotherapy. Methods. Patients were randomly assigned to receive CY 2400 mg per M2 as a single- day dose and VCR 1.4 mg per M2 given on Day 1 or Day 9 after the CY. Results. There were 108 cases suitable for analysis. No difference in objective response (17.6%, 23.5%), subjective response, remission duration, or survival was observed in the two treatment arms. Conclusions. The authors conclude that a single, high dose of cyclophosphamide is more toxic and provides equal or less response than the equivalent dose given over 4 consecutive days and that no improved effect was detected using timed- sequential therapy with VCR.

Original languageEnglish (US)
Pages (from-to)2113-2118
Number of pages6
JournalCancer
Volume73
Issue number8
StatePublished - 1994

Fingerprint

Vincristine
Multiple Myeloma
Cyclophosphamide
Poisons
Therapeutics
Drug Therapy
Survival

Keywords

  • cyclophosphamide
  • multiple myeloma
  • time sequential treatment
  • vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma. / Lenhard, Raymond; Kalish, L. A.; Oken, M. M.; Ettinger, David S; Glick, J.

In: Cancer, Vol. 73, No. 8, 1994, p. 2113-2118.

Research output: Contribution to journalArticle

@article{663d1deafa9d4828aec5349f7c767a1b,
title = "Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma",
abstract = "Background. This study was designed to examine the efficacy and toxicity of high-dose cyclophosphamide (CY), and to evaluate the potential added effect of vincristine (VCR) given at a theoretic time of malignant cell stimulation in a group of patients with multiple myeloma, refractory to or relapsing after, treatment with standard doses of chemotherapy. Methods. Patients were randomly assigned to receive CY 2400 mg per M2 as a single- day dose and VCR 1.4 mg per M2 given on Day 1 or Day 9 after the CY. Results. There were 108 cases suitable for analysis. No difference in objective response (17.6{\%}, 23.5{\%}), subjective response, remission duration, or survival was observed in the two treatment arms. Conclusions. The authors conclude that a single, high dose of cyclophosphamide is more toxic and provides equal or less response than the equivalent dose given over 4 consecutive days and that no improved effect was detected using timed- sequential therapy with VCR.",
keywords = "cyclophosphamide, multiple myeloma, time sequential treatment, vincristine",
author = "Raymond Lenhard and Kalish, {L. A.} and Oken, {M. M.} and Ettinger, {David S} and J. Glick",
year = "1994",
language = "English (US)",
volume = "73",
pages = "2113--2118",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma

AU - Lenhard, Raymond

AU - Kalish, L. A.

AU - Oken, M. M.

AU - Ettinger, David S

AU - Glick, J.

PY - 1994

Y1 - 1994

N2 - Background. This study was designed to examine the efficacy and toxicity of high-dose cyclophosphamide (CY), and to evaluate the potential added effect of vincristine (VCR) given at a theoretic time of malignant cell stimulation in a group of patients with multiple myeloma, refractory to or relapsing after, treatment with standard doses of chemotherapy. Methods. Patients were randomly assigned to receive CY 2400 mg per M2 as a single- day dose and VCR 1.4 mg per M2 given on Day 1 or Day 9 after the CY. Results. There were 108 cases suitable for analysis. No difference in objective response (17.6%, 23.5%), subjective response, remission duration, or survival was observed in the two treatment arms. Conclusions. The authors conclude that a single, high dose of cyclophosphamide is more toxic and provides equal or less response than the equivalent dose given over 4 consecutive days and that no improved effect was detected using timed- sequential therapy with VCR.

AB - Background. This study was designed to examine the efficacy and toxicity of high-dose cyclophosphamide (CY), and to evaluate the potential added effect of vincristine (VCR) given at a theoretic time of malignant cell stimulation in a group of patients with multiple myeloma, refractory to or relapsing after, treatment with standard doses of chemotherapy. Methods. Patients were randomly assigned to receive CY 2400 mg per M2 as a single- day dose and VCR 1.4 mg per M2 given on Day 1 or Day 9 after the CY. Results. There were 108 cases suitable for analysis. No difference in objective response (17.6%, 23.5%), subjective response, remission duration, or survival was observed in the two treatment arms. Conclusions. The authors conclude that a single, high dose of cyclophosphamide is more toxic and provides equal or less response than the equivalent dose given over 4 consecutive days and that no improved effect was detected using timed- sequential therapy with VCR.

KW - cyclophosphamide

KW - multiple myeloma

KW - time sequential treatment

KW - vincristine

UR - http://www.scopus.com/inward/record.url?scp=0028217016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028217016&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 2113

EP - 2118

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -